title: Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours.
abstract: BACKGROUND
  This study sought to determine the safety of single agent capecitabine, a pro-drug of 5FU, in patients with metastatic non-pancreatic neuroendocrine tumours (NETs).
  
  
  METHODS
  Multicentre phase II, first-line study design. Oral capecitabine was administered on days 1-14 of 3-week cycles.
  
  
  RESULTS
  Treatment was safe and well tolerated. Common toxicities were diarrhoea and fatigue.
  
  
  CONCLUSIONS
  The study provides evidence to support the use of capecitabine as a substitute for infusional 5FU in the management of NETs.
authors.affiliation: University Department of Medical Oncology, Cancer and Haematology Centre, Churchill Hospital, Headington OX3 7LJ, UK.
authors.forename: L
authors.initials: L
authors.lastname: Medley
authors.forename: A N
authors.initials: AN
authors.lastname: Morel
authors.forename: D
authors.initials: D
authors.lastname: Farrugia
authors.forename: N
authors.initials: N
authors.lastname: Reed
authors.forename: N
authors.initials: N
authors.lastname: Hayward
authors.forename: J M
authors.initials: JM
authors.lastname: Davies
authors.forename: O
authors.initials: O
authors.lastname: Kirichek
authors.forename: R V
authors.initials: RV
authors.lastname: Thakker
authors.forename: D C
authors.initials: DC
authors.lastname: Talbot
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D000069287:Capecitabine; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000188:drug therapy; D018358:Neuroendocrine Tumors / Q000188:drug therapy*
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil